- Home
- BRY vs ATYR Comparison
BRY vs ATYR Comparison
Compare BRY & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRY
- ATYR
- Stock Information
- Founded
- BRY 1909
- ATYR 2005
- Country
- BRY United States
- ATYR United States
- Employees
- BRY N/A
- ATYR N/A
- Industry
- BRY Oil & Gas Production
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRY Energy
- ATYR Health Care
- Exchange
- BRY Nasdaq
- ATYR Nasdaq
- Market Cap
- BRY 249.1M
- ATYR 105.8M
- IPO Year
- BRY N/A
- ATYR 2015
- Fundamental
- Price
- BRY $3.37
- ATYR $1.00
- Analyst Decision
- BRY Hold
- ATYR Buy
- Analyst Count
- BRY 2
- ATYR 6
- Target Price
- BRY $4.00
- ATYR $8.88
- AVG Volume (30 Days)
- BRY 1.4M
- ATYR 13.3M
- Earning Date
- BRY 11-06-2025
- ATYR 11-06-2025
- Dividend Yield
- BRY 3.59%
- ATYR N/A
- EPS Growth
- BRY N/A
- ATYR N/A
- EPS
- BRY 0.07
- ATYR N/A
- Revenue
- BRY $701,914,000.00
- ATYR N/A
- Revenue This Year
- BRY N/A
- ATYR $420.85
- Revenue Next Year
- BRY N/A
- ATYR $1,513.40
- P/E Ratio
- BRY $51.34
- ATYR N/A
- Revenue Growth
- BRY N/A
- ATYR N/A
- 52 Week Low
- BRY $2.11
- ATYR $0.68
- 52 Week High
- BRY $5.90
- ATYR $7.29
- Technical
- Relative Strength Index (RSI)
- BRY 39.06
- ATYR 31.34
- Support Level
- BRY $3.60
- ATYR $0.90
- Resistance Level
- BRY $3.52
- ATYR $1.12
- Average True Range (ATR)
- BRY 0.14
- ATYR 0.09
- MACD
- BRY -0.08
- ATYR 0.18
- Stochastic Oscillator
- BRY 5.97
- ATYR 72.63
About BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.